Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ZANAMIVIR

All products: Limited Use (codes 414, 415)

Other products in the same Health Canada class (J05A, J05AH) — coverage varies; not interchangeable

  • Oseltamivir (Tamiflu): limited Use 371, 372, 639, Not a benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Acyclovir (Zovirax): general benefit, Not a benefit
  • Atazanavir (Reyataz): general benefit, Not a benefit

48 more in the class list below

Relenza · DIN 02240863 · 5mg · Pd Inh-5 Rotadisks Pk

Limited Use — Reason for Use code 414, 415 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 414, 415 required
Write on scriptLU code 414, 415 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 414, 415
Coverage limit: For the treatment or prophylaxis of institutionalized individuals during confirmed outbreaks due to influenza A or Influenza B when the predominant circulating strain is resistant to oseltamivir or for the prophylaxis of influenza A, where new cases have developed despite amantadine prophylaxis. The outbreak must be confirmed by Public Health. Reason for Use code 414 For treatment: 2 inhalations of 5mg (10mg) bid for 5 days, Coverage limit: LU Authorization Period: 1 year Reason for Use code 415 For prophylaxis: 2 inhalations of 5mg (10mg) once daily for 10 days. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Relenza · DIN 02240863 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2010-03-02 Health Canada: Marketed since 2003-11-13 · brand RELENZA · ATC J05AH01 ZANAMIVIR · form Powder · route Inhalation, Oral · ingredients ZANAMIVIR 5 MG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Relenza: Formulary list price $50.1700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $50.1700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64454 · Verify on the e-Formulary ↗ (DIN 02240863)

Source record
DIN 02240863: Relenza Raw flags: sec12=Y, sec3=Y Item: 081800109; group id 117; item number 0200; lccId 00203; manufacturer id GSK Source form: Pd Inh-5 Rotadisks Pk; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $50.1700; ministry $50.1700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240863 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64454
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

OSELTAMIVIR PHOSPHATE

· 15 products · Limited Use, codes 371, 372, 639 (13), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 30mg, 45mg, 75mg, 6mg/mL · Cap, O/L

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab

DARUNAVIR

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 600mg, 800mg · Tab

DARUNAVIR & COBICISTAT

· 1 products · General benefit · strengths: 800mg & 150mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: uncomplicated illness
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. OSELTAMIVIR PHOSPHATE · Limited Use, codes 371, 372, 639 (13), Off-Formulary Interchangeable, not an ODB benefit (2) Indications TAMIFLU (oseltamivir phosphate, capsules and powder for oral suspension) is indicated for: • The treatment of uncomplicated acute illness due to influenza infection in adults and adolescents (≥ 13 years) who have been symptomatic for no more than 2 days. PM: https://pdf.hres.ca/dpd_pm/00085655.PDF; date 2026-08-05; DIN 02241472; fetched 2026-09-10 Product monograph • The treatment of uncomplicated acute illness due to influenza infection in adults and adolescents (≥ 13 years) who have been symptomatic for no more than 2 days. The treatment indication is based on two Phase III clinical studies of naturally occurring influenza in adults in which the predominant infection was influenza A (95%) and a limited number with influenza B (3%) and influenza of unknown type (2%), reflecting the distribution of these strains in the community. The indication is also supported by influenza A and B challenge studies. No data are available to support the safety and efficacy of TAMIFLU in adult patients who commenced treatment after 40 hours of onset of symptoms. PM: https://pdf.hres.ca/dpd_pm/00085655.PDF; date 2026-08-05; DIN 02241472; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Treatment of Influenza RELENZA (zanamivir dry powder for inhalation) is indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years of age and older, who have been symptomatic for no more than 2 days. No data are available to support zanamivir safety and efficacy in patients who receive treatment after 48 hours of symptoms. This indication is based on placebo controlled studies conducted in North America, the Southern Hemisphere, and Europe during their respective influenza seasons. The magnitude of treatment effect varied between studies, with possible relationships to population-related factors including amount of symptomatic relief medication used. RELENZA, when taken as recommended for treatment of influenza, alleviates the symptoms and reduces their duration. Prophylaxis of Influenza RELENZA is indicated in adults and pediatric patients 7 years of age and older for prophylaxis of influenza. Important Information on Use of RELENZA RELENZA is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstruc… https://pdf.hres.ca/dpd_pm/00046474.PDF PM date: July 20, 2018 Source product: RELENZA; DIN 02240863; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.